Kliniske studier for Gliom i North Carolina
16 studier for Gliom søker deltakere på steder i North Carolina.
Byer i North Carolina
Offisiell studietekst (engelsk)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Novant Health Presbyterian Medical Center, Charlotte
- East Carolina University, Greenville
- Wake Forest University Health Sciences, Winston-Salem
RekruttererFase 1/2
12 Months – 21 Years · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05099003A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
RekruttererFase 1/2
Opp til 25 år · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04094610ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Duke University Medical Center, Durham
RekruttererFase 2
12 Months – 39 Years · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06838676Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
RekruttererObservasjonsstudie
12 Months – 39 Years · Alle kjønn · Oppdatert 8. sep. 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
RekruttererFase 2
Alder 12 til 39 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT05303519ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
- Duke University Medical Center, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05609994PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Duke Cancer Center, Durham
RekruttererFase 2
Alder 3 til 39 · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05096481MRI in High-Grade Glioma Patients Undergoing Chemoradiation
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05212272A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797Lerapolturev (PVSRIPO) in GBM
- Duke University Medical Center, Durham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. jul. 2026 · NCT06177964Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
RekruttererTidlig fase 1Frivillige helsepersonell ønskes velkommen
Alder 1 til 21 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT06333899Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- Duke University Medical Center, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 4. jun. 2026 · NCT04547777Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
RekruttererFase 2
12 Months – 39 Years · Alle kjønn · Oppdatert 29. mai 2026 · NCT05843253Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- Duke University, Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. apr. 2026 · NCT06126744A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Duke University Health System, Durham
RekruttererTidlig fase 1
Opp til 21 år · Alle kjønn · Oppdatert 18. mar. 2026 · NCT04655404Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.